|Bid||13.00 x 800|
|Ask||13.01 x 900|
|Day's Range||11.16 - 13.40|
|52 Week Range||11.16 - 32.74|
|Beta (3Y Monthly)||2.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.64|
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on December 6, it received a letter from the U.S. Food and Drug Administration (FDA) indicating that a partial clinical hold has been placed on its Phase 1 monotherapy study of MGD009, a B7-H3 × CD3 bispecific DART® molecule, as well as on a combination study of MGD009 and MGA012 (anti-PD-1). Under the partial clinical hold, no new patients will be enrolled in either study until the partial hold is lifted by the FDA. Current study participants may continue to receive drug at their pre-assigned dose.
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced clinical data from an ongoing Phase 1 study of flotetuzumab, MacroGenics’ CD123 x CD3 bispecific DART molecule, in two oral and two poster presentations at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place in San Diego, CA on December 1-4, 2018. The Phase 1 dose expansion study of flotetuzumab in relapsed/refractory patients with acute myeloid leukemia (AML) enrolled 31 patients at the recommended Phase 2 dose of 500 ng/kg/day by continuous infusion with a lead-in dosing strategy.
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Margetuximab, an immune-optimized anti-HER2 monoclonal antibody currently being evaluated in Phase 3 metastatic breast cancer with anticipated topline results in the first quarter of 2019. Zai Lab obtains regional development and commercialization rights for these programs in mainland China, Hong Kong, Macau and Taiwan.
ROCKVILLE, MD, Nov. 27, 2018 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.
On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus will be on the company's launch and commercialization plans for its newly approved anti-epileptic drug Epidiolex.
Cara Therapeutics (CARA) is a clinical-stage biotechnology company developing new chemical entities for managing pain and pruritus. Cara Therapeutics reported EPS of -$0.52 on revenue of $2.87 million in the second quarter.
P.A.W. Capital Partners is a Greenwich-based hedge fund launched at the end of 1990 by its current Chief Investment Officer, General Partner and Senior Portfolio Manager, Peter A. Wright. After leading his fund for 28 years, and considering his previous work history, Peter Wright has more than 30 years of experience in the securities industry. […]
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 81 cents. The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment ...
Margetuximab: Phase 3 SOPHIA study enrollment completed; topline results 1Q 2019PD-1 franchise: MGD013 cohort expansions initiated; $15 million in MGA012 milestones triggered;.
MacroGenics, Inc. (MGNX) today announced that on Wednesday, November 7, 2018, the Company will release its financial results for the quarter ended September 30, 2018. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Wednesday, November 7, 2018 at 4:30 pm (ET). The recorded, listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investors section of the Company's website at http://ir.macrogenics.com/events.cfm.
NanoString Technologies, Inc. (NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that MacroGenics (MGNX) and NanoString have entered into a translational research agreement to identify and develop biomarkers for MacroGenics’ MGD013 program. Disrupting these non-redundant inhibitory pathways may further restore exhausted T-cell function and enhance anti-tumor efficacy. MacroGenics and NanoString will conduct joint research using the PanCancer IO 360™ Panel to explore potentially predictive signatures for MGD013 clinical applications.
MacroGenics’ management will participate in the conference in New York City and provide a corporate update on November 14, 2018, at 12:30 p.m. ET. Webcasts of the Credit Suisse and Stifel presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of MacroGenics Inc (NASDAQ:MGNX) as an investment opportunity by taking the expected Read More...
ROCKVILLE, MD, Sept. 26, 2018--. MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment ...